Selective estrogen receptor modulators

Climacteric

Volumn 1, Issue 2, 1998, Pages 143-147

  Kearney, C E ^a   Purdie, D W ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Antiestrogen; Estrogen; Menopause; Osteoporosis; Selective estrogen receptor modulators

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

AGED; ANIMAL; BREAST TUMOR; CHEMISTRY; ESTROGEN THERAPY; FEMALE; HUMAN; MIDDLE AGED; PHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; REVIEW;

AGED; ANIMALS; BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 0032098310     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.3109/13697139809085530     Document Type: Article

References (24)

1. Beall PT, Misra LK, Young RL, et al. Clomiphene protects against osteoporosis in the mature ovariectomized rat. Calcif Tissue Int 1984;36:123-5
2. Jordan VC, Phelps E, Lindgren JU. Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 1987;10:31-5
3. McNagny SE, Wenger NK, Frank E. Personal use of postmenopausal hormone replacement therapy by women physicians in the United States. Ann Intern Med 1997;127:1093-6
4. Purdie DW, Steel SA, Howey S, et al. The technical and logistical feasibility of population examination using DEXA and directed HRT intervention: with two year follow up. Osteoporosis Int 1996;3:S31-6
5. Henrich JB. The postmenopausal estrogen/breast cancer controversy. J Am Med Assoc 1992;268:1900-2
6. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93
7. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 101 811 women without breast cancer. Lancet 1997;350:1047-59
8. Grodstein F, Stamper MJ, Colditz GA, et al. Postmenopausal hormone replacement therapy and mortality. N Engl J Med 1997;336:1769-75
9. Turner RT, Wakley GK, Hannon KS, et al. Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. J Bone Miner Res 1987;2:449-56
10. Wakley GK, Baum BL, Hannon KS, et al. The effects of tamoxifen on the osteopenia induced by sciatic neurotomy in the rat: a histomorphometric study. Calcif Tissue Int 1988;43:383-8
11. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-6
12. Powles TJ, Jones AL, Ashley SE. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Br Cancer Res Treat 1994;31:73-82
13. McDonald CC, Stewart HJ. Cardiac and vascular morbidity of tamoxifen. Breast 1995;4:246
14. Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985;69:237-8
15. Fischer B, Costantino JP, Redmond CK. Endometrial cancer in tamoxifen treated breast cancer patients: findings NSABP B-14. J Natl Cancer Inst 1994;86:527-37
16. Buzdar AU, Marcus C, Holmes F, et al. Phase II evaluation of LY 156758 in metastatic breast cancer. Oncology 1988;45:344-5
17. Black LJ, Masahiko S, Rowley ER, et al. Raloxifene (LY 139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomised rats. J Clin Invest 1994;93:63-9
18. Draper MW, Flowers DE, Huster WJ, et al. Controlled trial of raloxifene (LY 139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996:11:835-42
19. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in post menopausal women. N Engl J Med 1997;337:1641-7
20. Paech K, Webb P, Kuiper J, et al. Differential ligand activation of estrogen receptors ERa and ERß at API sites. Science 1997;277:1508-10
21. Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the estrogen receptor. Nature (London) 1997;389:753-8
22. Pennisi E. Differing roles found for estrogen's two receptors. Science 1997;277:1439
23. Purdie DW. Selective estrogen receptor modulation - HRT replacement therapy. Br J Obstet Gynaecol 1997;104:1103-5
24. Apelgern LD, Bailey DL, Fouts RL, et al. The effect of a selective estrogen receptor modulator on the progression of spontaneous autoimmune disease in MRL 1pr/lpr mice. Cell Immunol 1996;173:55-63